Drug-Eluting Balloon Versus Standard Balloon Angioplasty for Infrapopliteal Arterial Revascularization in Critical Limb Ischemia
Top Cited Papers
- 6 October 2014
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 64 (15), 1568-1576
- https://doi.org/10.1016/j.jacc.2014.06.1198
Abstract
Background: Drug-eluting balloons (DEB) may reduce infrapopliteal restenosis and reintervention rates versus percutaneous transluminal angioplasty (PTA) and improve wound healing/limb preservation. Objectives: The goal of this clinical trial was to assess the efficacy and safety of IN.PACT Amphirion drug-eluting balloons (IA-DEB) compared to PTA for infrapopliteal arterial revascularization in patients with critical limb ischemia (CLI). Methods: Within a prospective, multicenter, randomized, controlled trial with independent clinical event adjudication and angiographic and wound core laboratories 358 CLI patients were randomized 2:1 to IA-DEB or PTA. The 2 coprimary efficacy endpoints through 12 months were clinically driven target lesion revascularization (CD-TLR) and late lumen loss (LLL). The primary safety endpoint through 6 months was a composite of all-cause mortality, major amputation, and CD-TLR. Results: Clinical characteristics were similar between the 2 groups. Significant baseline differences between the IA-DEB and PTA arms included mean lesion length (10.2 cm vs. 12.9 cm; p = 0.002), impaired inflow (40.7% vs. 28.8%; p = 0.035), and previous target limb revascularization (32.2% vs. 21.8%; p = 0.047). Primary efficacy results of IA-DEB versus PTA were CD-TLR of 9.2% versus 13.1% (p = 0.291) and LLL of 0.61 ± 0.78 mm versus 0.62 ± 0.78 mm (p = 0.950). Primary safety endpoints were 17.7% versus 15.8% (p = 0.021) and met the noninferiority hypothesis. A safety signal driven by major amputations through 12 months was observed in the IA-DEB arm versus the PTA arm (8.8% vs. 3.6%; p = 0.080). Conclusions: In patients with CLI, IA-DEB had comparable efficacy to PTA. While primary safety was met, there was a trend towards an increased major amputation rate through 12 months compared to PTA. (Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia [INPACT-DEEP]; NCT00941733)Keywords
This publication has 29 references indexed in Scilit:
- Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal AngioplastyCirculation: Cardiovascular Interventions, 2012
- A Prospective Randomized Multicenter Comparison of Balloon Angioplasty and Infrapopliteal Stenting With the Sirolimus-Eluting Stent in Patients With Ischemic Peripheral Arterial DiseaseJournal of the American College of Cardiology, 2012
- Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemiaThe Lancet, 2011
- Angiographic patency and clinical outcome after balloon‐angioplasty for extensive infrapopliteal arterial diseaseCatheterization and Cardiovascular Interventions, 2010
- Why we should be wary of single-center trialsCritical Care Medicine, 2009
- Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemiaJournal of Vascular Surgery, 2009
- When is a technically successful peripheral angioplasty effective in preventing above‐the‐ankle amputation in diabetic patients with critical limb ischaemia?Diabetic Medicine, 2007
- Vascular Involvement in Diabetic Subjects with Ischemic Foot Ulcer: A New Morphologic Categorization of Disease SeverityEuropean Journal of Vascular and Endovascular Surgery, 2006
- Early and Five-year Amputation and Survival Rate of Diabetic Patients with Critical Limb Ischemia: Data of a Cohort Study of 564 PatientsEuropean Journal of Vascular and Endovascular Surgery, 2006
- The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: A 10-year experienceJournal of Vascular Surgery, 2005